866-997-4948(US-Canada Toll Free)

Bydureon (Type 2 Diabetes) - Forecast and Market Analysis to 2022

Published By :

GlobalData

Published Date : Jul 2013

Category :

Metabolic Disorders

No. of Pages : 46 Pages


GlobalData has released its new report, Bydureon (Type 2 Diabetes) Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs.

Bydureon (exenatide ER) was developed jointly by Amylin Pharmaceuticals and Eli Lilly. However, the two companies announced in 2011 the termination of a decade-long collaboration, and thus Bydureon was brought to market by Amylin Pharmaceuticals alone. Bydureon was approved by the EMA in 2011 and by the FDA in 2012. In 2012, Bristol-Myers Squibb officially acquired Amylin Pharmaceuticals.

Scope

  • Overview of type 2 diabetes, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
  • Detailed information on Bydureon including product description, safety and efficacy profiles as well as a SWOT analysis.
  • Sales forecast for Bydureon for the top ten countries from 2012 to 2022.
  • Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China.

Reasons to buy

  • Understand and capitalize by identifying products that are most likely to ensure a robust return
  • Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
  • Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
  • Make more informed business decisions from insightful and in-depth analysis of Bydureon performance
  • Obtain sales forecast for Bydureon from 2012-2022 in top ten countries (the US, France, Germany, Italy, Spain, the UK, Japan, Brazil, India and China)
Table of Contents

1 Table of Contents
1 Table of Contents 6
1.1 List of Tables 8
1.2 List of Figures 8

2 Introduction 9
2.1 Catalyst 9
2.2 Related Reports 10

3 Disease Overview 13
3.1 Etiology and Pathophysiology 13
3.1.1 Etiology 13
3.1.2 Pathophysiology 14
3.1.3 Prognosis 15
3.1.4 Quality of Life 16
3.2 Symptoms 16

4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Diagnosis and Referrals 18
4.1.2 Treatment Guidelines 19

5 Competitive Assessment 25
5.1 Overview 25
5.2 Strategic Competitor Assessment 26

6 Bydureon (exenatide ER) 28
6.1 Overview 28
6.2 Efficacy 29
6.3 Non-glycemic Benefits 30
6.4 Safety 31
6.5 SWOT Analysis 31
6.6 Forecast 32

7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 36
7.3 Methodology 37
7.4 Forecasting Methodology 37
7.4.1 Diagnosed Type 2 Patients 37
7.4.2 Percent Drug-Treated Patients 38
7.4.3 Drugs Included in Each Therapeutic Class 38
7.4.4 Launch and Patent Expiry Dates 39
7.4.5 General Pricing Assumptions 39
7.4.6 Individual Drug Assumptions 40
7.5 Physicians and Specialists Included in this Study 41
7.6 About the Authors 43
7.6.1 Analyst II - CVMD 43
7.6.2 Therapy Director - CVMD and Infectious Disease 43
7.6.3 Global Head of Healthcare 44
7.7 About GlobalData 45
7.8 Disclaimer 45

List of Table


Table 1: Symptoms of Type 2 Diabetes 17
Table 2: Diagnostic Tests and Typical Criteria for Type 2 Diabetes 18
Table 3: Treatment Guidelines for Type 2 Diabetes 20
Table 4: Most-Prescribed Drugs (Following Metformin and Sulfonylureas) for Type 2 Diabetes by Class in the Global Markets, 2012 23
Table 5: Leading Branded Treatments for Type 2 Diabetes, 2012 27
Table 6: Product Profile - Bydureon 29
Table 7: Bydureon SWOT Analysis, 2012 31
Table 8: Global Sales Forecasts ($m) for Bydureon, 2012-2022 32
Table 9: Key Launch Dates 39
Table 10: Key Patent Expiry Dates 39
Table 11: Number of High-Prescribing Physicians Surveyed 42

List of Chart


Figure 1: ADA/EASD General Recommendations for Antihyperglycemic Therapy 22

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *